CAS 1629869-44-8
:Pimodivir
Description:
Pimodivir, with the CAS number 1629869-44-8, is an antiviral compound primarily investigated for its potential in treating influenza virus infections. It functions as a polymerase acidic (PA) endonuclease inhibitor, which disrupts the viral replication process by targeting the viral RNA polymerase complex. This mechanism of action makes it a candidate for addressing influenza strains that may be resistant to conventional antiviral therapies. Pimodivir has shown activity against various influenza virus subtypes in preclinical studies, indicating its broad-spectrum potential. The compound is characterized by its specific chemical structure, which contributes to its biological activity and selectivity. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile in clinical settings. Ongoing research aims to further elucidate its therapeutic potential and optimize its use in managing influenza outbreaks, particularly in populations at high risk for severe disease.
- Vx-787
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.
Pimodivir
CAS:<p>Pimodivir (VX-787), an influenza A virus polymerases inhibitor via oral, interacts with the viral PB2 subunit.</p>Formula:C20H19F2N5O2Purity:99.35% - 99.62%Color and Shape:SolidMolecular weight:399.39Pimodivir
CAS:<p>Pimodivir is a non-nucleoside-derived inhibitor of the polymerase basic protein 2 (PB2) subunit found in the polymerase complex of the influenza A virus. In general, pimodivir is indicated for the treatment of patients with severe influenza although knowledge about possible rise of resistance is not available.</p>Formula:C20H19F2N5O2Purity:Min. 95%Color and Shape:Slightly Yellow PowderMolecular weight:399.39 g/mol
